<document id="DDI-DrugBank.d641">
    <sentence id="DDI-DrugBank.d641.s0" text="ALIMTA is primarily eliminated unchanged renally as a result of glomerular filtration and tubular secretion. ">
        <entity charOffset="0-5" id="DDI-DrugBank.d641.s0.e0" text="ALIMTA" type="brand" />
    </sentence>
    <sentence id="DDI-DrugBank.d641.s1" text="Concomitant administration of nephrotoxic drugs could result in delayed clearance of ALIMTA. ">
        <entity charOffset="85-90" id="DDI-DrugBank.d641.s1.e0" text="ALIMTA" type="brand" />
    </sentence>
    <sentence id="DDI-DrugBank.d641.s2" text="Concomitant administration of substances that are also tubularly secreted (e.g., probenecid) could potentially result in delayed clearance of ALIMTA. ">
        <entity charOffset="81-90" id="DDI-DrugBank.d641.s2.e0" text="probenecid" type="drug" />
        <entity charOffset="142-147" id="DDI-DrugBank.d641.s2.e1" text="ALIMTA" type="brand" />
        <pair ddi="true" e1="DDI-DrugBank.d641.s2.e0" e2="DDI-DrugBank.d641.s2.e1" id="DDI-DrugBank.d641.s2.p0" type="mechanism" />
    </sentence>
    <sentence id="DDI-DrugBank.d641.s4" text="Patients with mild to moderate renal insufficiency should avoid taking NSAIDs with short elimination half-lives for a period of 2 days before, the day of, and 2 days following administration of ALIMTA. ">
        <entity charOffset="71-76" id="DDI-DrugBank.d641.s4.e0" text="NSAIDs" type="group" />
        <entity charOffset="194-199" id="DDI-DrugBank.d641.s4.e1" text="ALIMTA" type="brand" />
        <pair ddi="true" e1="DDI-DrugBank.d641.s4.e0" e2="DDI-DrugBank.d641.s4.e1" id="DDI-DrugBank.d641.s4.p0" type="advise" />
    </sentence>
    <sentence id="DDI-DrugBank.d641.s6" text="If concomitant administration of an NSAID is necessary, patients should be monitored closely for toxicity, especially myelosuppression, renal, and gastrointestinal toxicity. ">
        <entity charOffset="36-40" id="DDI-DrugBank.d641.s6.e0" text="NSAID" type="group" />
    </sentence>
    </document>